GSK stock dips 0.6% after six-session gain streak. EU panel backs Blenrep for multiple myeloma, while FDA expands asthma ...

GSK and Spero ended a Phase 3 trial early meeting efficacy goals in cUTIs, positioning its treatment as the first oral ...

GSK (GSK) stock in focus as its antibody drug conjugate Blenrep gains EMA recommendation for relapsed multiple myeloma with ...

The pharma company said it expects more approvals through the year following positive results from a Phase 3 trial.

As pharma companies try to get more compounded GLP-1 users on branded versions of the drugs, they’re embracing certain ...

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the ...

Market Overview: The Global Nasal Polyposis Drugs Market is expanding rapidly, owing to advances in biologic medicines, minimally invasive surgical procedures, and personalized medicine approaches.

The smart inhalers market is experiencing significant growth, driven by the increasing incidence of respiratory diseases like asthma and COPD, technological advancements, widespread smartphone usage, ...

LONDON, GREATER LONDON, UNITED KINGDOM, May 29, 2025 /EINPresswire.com/ -- The urticaria market size has surged from $4.03 billion in 2024 to $4.77 billion in 2025, achieving a substantial compound ...

GSK’s antibody has not gained approval for COPD treatment in any other country. Credit: 1take1shot/Shutterstock. GSK has gained approval from the US Food and Drug Administration (FDA) for its ...

GSK’s linerixibat works by inhibiting the re-uptake of bile acids. Credit: MAXSHOT.PL / Shutterstock. GSK has reported positive outcomes from the randomised Phase III GLISTEN trial of the targeted ...